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Introduction
The incidence of HCC varies widely, being most
common in Southeast Asia sub-Saharan Africa and much
less in North America and Western Europe. Various
researchers from Pakistan have reported variable figures
about prevalence of HCC in cirrhosis, ranging from 3.7% to
16.7%.1 Some latest studies conducted in cirrhotic patients
have reported 10.96% prevalence of HCC in North Western
Frontier Province, 9.1% in Lahore and 8.25% in Karachi.
This prevalence rate is high when compared to Spain (6.6%)
but low when compared with Italy (19.7%) and Japan
(39%).2-4
In Pakistan HCC is the fourth most common hepatic
disorder. 5 In Asia, sonography is reported to have a high
sensitivity in the detection of HCC.6 Diagnostic accuracy of
USG has been reported as 80% in a prospective study of 32
cases of HCC.7 However, the reported numbers were based
primarily on retrospective evaluations of pathologically
proved cases. Reported sensitivities have been much lower
in the United States and Europe. 
The availability of helical CT has changed the
radiologist's approach to imaging. With the availability of
faster CT scanners it is now possible to scan through the
entire liver twice- once during the hepatic arterial phase
(HAP) and then the  portal venous phase (PVP) for
hypervascular liver tumor detection and lesion
characterization.
Patients and Methods
A prospective study was carried out over a  period of
20 months (1-4-2000 to 30-11-2001). Initially 87
consecutive patients were included in the study who
presented to the department as diagnosed cases or suspected
HCC either by USG or raised serum a-fetoprotein level.
Forty patients were selected who were biopsy proven HCC
and 47 patients were excluded due to inadequate records or
not proven HCC on pathologic results.
Out of the 40 patients, 26 were males, with age range
between 30 to 85 years (mean 55 years). All these patients
had proven HCC on histopathology and complete records,
including CT scans, medical history and pathology reports
All 40 patients were diagnosed to have HCC by pathological
findings with percutaneous core-needle biopsy (n=40) along
with abrupt elevation of serum a-fetoprotein level (n=16)
and definite tumor growth on follow up USG or CT (n=5).
Thirty five patients had USG before CT examination, while
none had MRI or nuclear scanning.  In all  patients with
HCC, biphasic CT findings were compared and correlated
with histopathologic findings and characteristic clinical
manifestations.
CT Imaging Protocol
Helical CT scanning of the liver was performed with
CTi/Pro GE Medical system at 120 kvp and 200-250 mAs.
All patients received oral contrast material (1 liter of 2%
Gastrograffin) 1 hour before CT examination, followed by
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Abstract
Objective: To evaluate the role of biphasic contrast-enhanced helical CT including Hepatic Arterial Phase (HAP)
imaging with Portal Venous Phase (PVP) imaging, in the detection and characterization of hepatocellular
carcinomas.
Methods: The study included 40 patients (M=26, F=14) with histopathologically proven  HCC. Age range was
between 30-85 years (mean=55) by following consecutive patients with cirrhosis in whom Hepatocellular
carcinoma was diagnosed or suspected either by raised serum a (alpha)-fetoprotein level or Ultrasound.
Results: Biphasic contrast-enhanced examination revealed a total of 85 lesions in these 40 patients, out of
which 13 were unifocal, 12 showed a dominant mass with satellite lesions, 2 showed cluster of contiguous
nodules and 13 were multifocal HCCs. 
Mean diameter was 3.1 cm, ranging from 0.8 to 14 cm. On HAP imaging 85% were detected. (hyperattenuating
= 69, hypoattenuating = 3) while on PVP imaging detectibility was only 48% (hyperattenuating=2,
hypoattenuating=39). Hence detectibility was significantly (p=0.008) superior in HAP as compared to PVP
imaging. In 7 patients (17%) tumor was visible only on HAP images. Venous invasion was present in 12 patients
(30%) while arterio-portal shunting was seen in 5 patients (13%).
Conclusion: Biphasic contrast enhanced helical CT is a useful method in detection and characterization of HCC
(JPMA 54:123;2004).
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I/V injection of 100 ml nonionic contrast medium for
detection and enhancement pattern of the lesions. Contrast
was administered with power injector at flow rate of 4
ml/sec (injected in 25 seconds). Biphasic Helical CT scans
were obtained in HAP obtained after 20 sec. delay and in
PVP after 50-60 sec. delay following the injection of I/V
contrast material. In the HAP, slice thickness of 5mm with
5mm inter-slice space and pitch used was 1-1.5 depending
upon the liver size. The entire liver for HAP was scanned in
one breath hold. Later, additional images of PVP were
obtained from the dome of diaphragm to the iliac crest with
7mm slice thickness and 7mm space. The hepatic arterial
phase and portal venous phase images in 40 patients with 85
HCCs were compared and assessed for detection and
enhancement pattern of the tumors. Any associated finding
was sought, I.V.C or biliary ductal infiltration and hepatic or
para-aortic lymphadenopathy.  Arterio-portal shunting,
ascites and pleural effusion if present was noted.
Statistical Analysis
Statistical analysis was performed with the help of a
statistician. For comparison of detection of lesions in
arterial and venous phase, statistical analysis was performed
by using Repeated Measures Design. Statistical data
analysis was done by using computer programme SPSS
(version 8.0). A p-value of less than 0.05 was considered to
indicate statistically significant difference. To find out
whether size difference of lesions affected the detectibility
Tukey's HSD (Honest Significance Difference) test for
multiple comparisons was used with level of confidence as
a = 5%.8
Results
Evaluation of enhancement pattern and detectibility in
40 patients with 85 HCCs using biphasic helical CT was
performed. Of 85 HCCs, 69 (81%) showed moderate to
marked hyperattenuation during the hepatic arterial phase.
There was total hyperattenuation in 43 and partial
hyperattenuation in 26. The remaining 16 HCCs showed
isoattenuation in 13 (15%) and hypoattenuation in 3 (3.5%)
during the hepatic arterial phase of imaging. Therefore the
detectibility of HCC in the HAP of helical CT was 85%
(hyperattenuating=69, hypoattenuating=3). Detectibility was
determined by hyperattenuation or hypoattenuation
compared to surrounding enhancing liver. Most of the HCCs
showed characteristic hyperattenuation in the HAP before
adequate enhancement of liver parenchyma. This was true
even in HCCs <1 cm in diameter.  
The PVP images showed hyperattenuation in 2
(2.3%), isoattenuation in 42 (49%), and hypoattenuation in
41 (48%). The detectability of HCCs in the PVP was 51%
(hyperattenuating = 2, hypoattenuating = 41) 
The detectibility of HCCs in HAP imaging was
significantly (p = 0.0008) superior to the PVP, calculated by
using Repeated Measures Test. Lesions were then divided
into groups of three sizes (<3 cm, 3-5 cm and >5 cm) for
comparison. There was significant difference in detection of
lesions of different sizes. (p-value=0.006) Honest
significance difference (HSD) value calculated by formula: 
HSD =q (a t N-t)ÖMSE/n, where, a = selected
significance level, T = no. of patients, N = total no. of
observations, MSE= within subjects mean square error and
n = no. of observation per group.
Note:  q (a t N-t) was obtained from studentized
range table.
The value was 0.4937. 
|c1-c2| = 0.65 > 0.4937
|c1-c3|= 0.5125> 0.4937
|c2-c3|= 0.1352< 0.4937
Where, c1= mean of <3 cm sized lesions, c2= mean
of 3-5 cm sized lesions, c3= mean of >5 cm sized lesions 
Multiple comparisons among the three size groups
using the Tukey's HSD Test lead to the conclusion that mean
number of lesions with size <3 cm were significantly
different from the mean number of lesions having size 3-5
cm and 5 cm or above. 
The reason for this difference is explained by the fact
that poorly-differentiated HCCs are usually hypervascular
and receive a large arterial blood supply since the portal
blood supply tends to decrease progressively as the grade of
malignancy increases.9 In contrast well-differentiated HCCs,
as is frequently the case with small HCCs are sometimes
hypovascular and as suggested by Ohashi et al.10 are better
detected when liver parenchyma enhances i.e. in PVP. 
Of the 85 HCCs, 16 HCCs (19%) did not show the
characteristic enhancement pattern in the hepatic arterial
Table. Diagnostic accuracy of two phases.
Tumour No. of Hepatic Portal
size (cm) lesions arterial phase venous phase
Correctly Sensitivity Correctly Sensitivity
detected (%) detected (%)
< 3 52 40 77 29 56
3-5 14 14 100 4 29
>5 19 18 95 10 53
Total 85 72 84 43 51
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phase of imaging. They were iso or hypodense and were
difficult to differentiate from other hepatic tumors including
metastases or intrahepatic cholangiocarcinoma. Therefore
the detectibility of hypervascular HCCs in the hepatic
arterial phase according to characteristic enhancement
pattern was 79%.
Capsular enhancement although better seen on
delayed images was identified in 8 (9%) of 85 tumor on
portal venous phase. When the enhancement pattern of
HCCs in the hepatic arterial phase was correlated with
tumor size, 38 of the 52 HCCs <3 cm in diameter were
hyperdense; 30 showed total hyperattenuation and 8 partial
hyperattenuation. In cases of 3 to 5cm HCCs, the lesions
were hyperdense in 13 of 14 HCCs, 8 showed total
hyperattenuation and 5 partial hyperattenuation. 
However, in cases of HCCs >5cm, the lesions were
hyperdense in 18 of the 19 HCCs; 5 showed total
hyperattenuation and 13 mosaic hyperattenuation. The
enhancement pattern of HCCs such as total or partial
enhancement in the hepatic arterial phase depended on
tumor size. Majority of tumors of 3 cm or greater size
enhanced confirming them as hypervascular HCCs. These
were mostly poorly-differentiated HCCs on histopathology.  
Three cases of HCC were complicated with bile duct
invasions. Two of these three HCCs were poorly defined,
infiltrative lesions that showed heterogenous
hyperattenuation during the hepatic arterial phase.
However, these two lesions showed hypoattenuation in
portal venous phase without capsular enhancement,
mimicking intrahepatic cholangiocarcinomas. The lesions
were pathologically confirmed as HCCs by percutaneous
core needle biopsy.
Twenty seven (67%) of the 40 patients with HCCs
had associated liver cirrhosis on CT images, and the
remaining 13 patients had associated chronic hepatitis or
liver cirrhosis on clinical findings and USG images.
Amongst the secondary findings detected by CT, ascites was
the most common manifestation of HCC. Varices and lymph
node enlargement at the porta hepatis were the other major
secondary findings. Venous invasion including the portal
vein and hepatic vein was present in (30%) of 40 patients.
The frequency of venous invasion was higher in larger HCCs
and seen better in portal venous phase. Arterio-portal
shunting was better seen in HAP in 5 (12.5%) of 40 patients. 
Discussion
It is important to perform CT scans during the
hepatic arterial phase for the diagnosis of HCC.11.12 The
enhancement pattern of HCC during the arterial phase
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imaging depends on tumor vascularity, tumor size, presence
of peliotic change in the tumor, and the degree of cirrhosis
in the surrounding liver parenchyma.13 Factors affecting
enhancement patterns of HCC include the volume of
contrast material used, length of scan delay after injection of
intravenous contrast material and rate of injection of
contrast material.11,12
Matsui et al.9 reported that early HCC is usually
hypovascular and intranodal portal blood flow tends to
decrease as the grade of malignancy increases. In addition,
the poorly differentiated HCC are usually hypervascular,
whereas well-differentiated HCCs are usually hypovascular,
particularly in cases of small-sized tumors.10,13,14 The
detection of hypervascular HCC in the arterial phase in this
study was 85% (72 of 85) confirming the benefit of biphasic
contrast-enhanced helical CT to optimally detect HCC, and
the results of Baron et al and Ohashi et al.10,15
Portal or hepatic venous invasion is considered to be
characteristic for HCC and associated with poor prognosis.
The frequency of venous invasion has been reported to vary
from 33 to 48%.16,17 In our study, portal venous invasion
was detected in 30% because images were obtained during
the portal venous phase. It was noted that the portal venous
phase images were not useful for the detection and
characterization of HCC because the lesions showed
isoattenuation in 49% (42 of 85 HCC).
CT studies in Asian populations have reported
encapsulated HCC in as many as 67% of tumors.14,17 In our
study only 9% of HCC showed capsular enhancement in the
portal venous phase because images were not acquired in
delayed phase, which better detects capsular enhancement.
Focal nodular hyperplasia, hepatic adenoma and
hypervascular metastases enhance during the arterial phase
and become isodense to hepatic parenchyma during the
portal venous phase.18 Therefore, HCC must be
differentiated from other hypervascular tumors in the
arterial phase. Although portal venous invasion and capsular
enhancement are features of HCC, CT findings are at times
nonspecific and difficult to differentiate other hypervascular
tumors from HCC. In our study two of the three HCCs with
bile duct invasion were poorly defined, infiltrative lesions
that showed heterogenous hyperattenuation in the hepatic
arterial phase without capsular enhancement, mimicking
cholangiocarcinomas.
The sensitivities of intraoperative USG, CT arterial
portography, and iodized oil CT have been reported to be
significantly higher than those of USG, CT or
angiography.14 However these methods being invasive are
not commonly used. In our study, however ready depiction
of small satellite nodules or intrahepatic metastases of HCC
was possible because of adequate enhancement in the
hepatic arterial phase. 
Since the biphasic helical CT does not have 100%
sensitivity for detection of HCC, some lesion are liable to be
missed especially the early HCC, as mentioned by Takayasu
et al.19 which results in false-negative findings.
Consequently the true- sensitivity, specificity and accuracy
of biphasic helical CT was also not possible.
In our study HAP images depicted 33% additional
HCC in 16 patients (40%) while HAP was the only phase to
depict tumors in 7 (18%). The results of our study are
comparable to studies by Oliver et al and Baron et al. The
only difference was the greater lesion detection in HAP
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alone (58%) despite the less number of patients. In western
literature it has been reported that the addition of HAP to
PVP images depicted 34% additional HCC in
approximately one-third of patients while HAP was the only
phase to depict tumor in 8-11% of patients.15,20 With the
advent of multi-detector helical CT, detection and
characterization of hepatocellular carcinoma has markedly
improved. Multidetector helical CT with its increased
spatial and temporal resolution allows multiple perfusion
phases of liver to be acquired.21,22
In patients suspected of having hypervascular
lesions which include hepatocellular carcinoma and in
patients scheduled for liver surgery, a biphasic study should
be performed routinely because clinical staging and surgical
resectability criteria rely on the accurate accounting of the
number and location of tumor nodules.
References
1. Jamal Q, Jaffarey NA, Aslam SM. A review of unusual liver tumors. J Pak
Med Assoc 1989;39:53-6.
2. Javed IF, Rukhsana JF. Prevalence of hepatocellular carcinoma in Pakistan in
liver cirrhosis: An experience in NWFP. J Coll Physicians Surg Pak
2000;2:54-5.
3. Zahir N, Mubarik A, Abdullah P. Spectrum of histopathological lesions in
liver biopsies at PNS Shifa, Karachi. J Coll Physicians Surg Pak
1998;6:255-7.
4. Riaz S, Azhar R , Hameed S. Pattern of liver diseases at Sheikh Zayed
Hospital, Lahore. Pak J Med Res 1995;34:91-4.
5. Riaz S, Azhar R, Hameed S. Pattern of liver diseases at Lahore. Pak  J Pathol
1995;6:5-9.
6. Takayasu K, Moriyama N, Muramatsu Y. The diagnosis of small
hepatocellular carcinomas: efficacy of various imaging procedures in 100
patients. Am J Roentgenol 1990;155:49-54.
7. Shah G, Qureshi IA, Hakim T, et al. Radiological aspects of hepatocellular
carcinoma: a hospital based study. Pak Armed Forces Med. J 1999;49:54-7.
8. Lyman O. Experiment with repeated measures. In: An introduction to
statistical methods and data analysis.ed. Lyman O. 3rd ed. London: PWS-Kent
Pub Co. 1984, pp. 793-807.
9. Matsui O, Kadoya M, Kameyama T. Benign and malignant nodules in
cirrhotic liver: distinction based on blood supply. Radiology 1991;198:493-7.
10. Ohashi I, Hanafusa K, Yoshida T. Small hepatocellular carcinoma: two phase
dynamic incremental CT in detection and evaluation. Radiology
1993;189:851-5.
11. Dodd GD III, Baron RL. Investigation of contrast enhancement in CT of liver:
the need for improved methods. Am J Roentgenol 1993;160:643-5.
12. Kihara Y, Tamura S, Yuki Y. Optimal timing for delineation of hepatocellular
carcinoma in dynamic CT. J Comput Assist Tomography 1993;17:719-22.
13. Honda H, Ochiai K, Adachi E. Hepatocellular carcinoma: correlation of CT,
angiographic, and histopathologic findings. Radiology 1993;189:857-62.
14. Choi BI, Takayasu K, Han MC. Small hepatocellular carcinomas and
associated nodular lesions of the liver: pathology, pathogenesis and clinical
findings. Am J Roentgenol 1993;160:1177-87.
15. Baron RL, Oliver JH, Dodd GD, et al. Hepatocellular carcinoma: evaluation
with biphasic, contrast-enhanced helical CT. Radiology 1996;199:505-11.
16. Stevens WR, Johnson CD, Stephens DH, et al. CT findings in hepatocellular
carcinoma: correlation of tumor characteristics with causative factors, tumor
size and histologic tumor grade. Radiology 1994;191:531-7.
17. Freeny PC, Baron RL, Teefey S. Hepatocellular carcinoma: reduced
frequency of typical findings with dynamic contrast-enhanced CT in a non-
Asian population. Radiology 1992;182:143-8.
18. Pattern RM, Byun JY, Freeny PC. CT of hypervascular hepatic tumors: are
unhanced scans necessary for diagnosis? Am J Roentgenol 1993;161:979-84.
19. Takayasu K, Furukawa H, Wakoo F. CT diagnosis of early hepatocellular
carcinoma: sensitivity, findings and CT-pathologic correlation. Am J
Roentgenol 1995;164:885-90. 
20. Oliver JH, Baron RL, Federle MP, et al. Detecting hepatocellular carcinoma:
the relative added value of using non-contrast and / or arterial phase imaging
in conjuction with conventional portal venous phase contrast CT. Am J
Roentgenol 1996;167:71-7. 
21. Foley WD. Special focus session: multidetector CT: abdominal visceral
imaging. Radiographics 2002;22:701-19.
22. Foley WD, Mallisee TA, Hohenwalter MD, et al.. Multiphase hepatic CT with
a multirow detector CT scanner.  Am J Roentgenol 2000;175:679-85.
J Pak Med Assoc127
